| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Related Medications Threads on Diabetes Health Forums
MannKind Corporation announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverage the unique rapid action of AFREZZA for use in a closed-loop blood sugar monitoring and insulin delivery system, termed the "artificial pancreas" by the JDRF. The study will be managed in conjunction with the Sansum Diabetes Research Institute and the University of California, Santa Barbara.
0 comments - Aug 29, 2010 -
Working toward the goal of unifying patients' diabetic treatment information in a single place, the PositiveID Corporation hopes to patent a new device that monitors insulin pens. The Insulin Tracker would attach to a user's insulin pen and record the times and amounts of injections. That information would then be sent to a database that allows for comprehensive monitoring. Insulin pens come in disposable and cartridge-replaceable flavors; the tracker can be moved easily from one pen to another.
0 comments - Aug 27, 2010 -
In the early days after my type 1 diabetes diagnosis, I sentenced a lot of foods to what I came to think of as my personal DO-NOT-EAT list, often with only slight provocation.
3 comments - Aug 25, 2010 -
Novo Nordisk announced today the availability of NovoDoseTM - the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk's modern insulin analog portfolio: Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).
1 comment - Aug 24, 2010 -
PPARy is a protein that regulates the body's production of fat cells. However, obesity can modify how PPARy works, leading to decreased insulin sensitivity and the development of metabolic syndrome. (Metabolic syndrome is the cluster of factors, including insulin resistance, overweight, high blood pressure, and abnormal blood sugar levels, that is a precursor to type 2 diabetes.)
0 comments - Aug 22, 2010 -
"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."
1 comment - Aug 12, 2010 -
The HEALTHY program, a three-year government-funded intervention in middle schools that was designed to lower overall rates of overweight and obesity among students, has produced mixed results.
2 comments - Aug 8, 2010 -
Bioengineers at the University of California, San Diego and GlySens Incorporated have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, published in the July 28, 2010 issue of the journal Science Translational Medicine, describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical trials and FDA approval, the device may be useful to people with diabetes as an alternative to finger sticking, and to short-term needle-like glucose sensors that have to be replaced every three to seven days.
4 comments - Jul 31, 2010 -
NEW YORK, NY, July 26, 2010 - Recalling the desperate fight for life that used to be waged by juvenile diabetes patients, and commemorating the events of 1921 that inaugurated a new era of hope for them and their families, the New York Historical Society will present the exhibition Breakthrough: The Dramatic Story of the Discovery of Insulin from October 5, 2010 through January 31, 2011. Exploring the roles of science, government, higher education and industry in developing and distributing a life-saving drug, the exhibition will bring to life the personalities who discovered insulin and raced to bring it to the world and will tell the story of one extraordinary New York girl-Elizabeth Evans Hughes, daughter of the leading statesman and jurist Charles Evans Hughes-who was among the very first patients to be saved.
1 comment - Jul 26, 2010 -
A massive study involving 485 people with type 1 diabetes at 30 locations across North America shows that the combination of an insulin pump and a continuous glucose monitor helps patients achieve significantly lower A1c levels than multiple daily insulin injections.
5 comments - Jul 13, 2010 -